Allocation of resources and psychosis

Australian and New Zealand Journal of Psychiatry

Volumn 37, Issue 1, 2003, Pages 15-23

  Neil, Amanda L ^a   Lewin, Terry J ^b   Carr, Vaughan J ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b HMRC   (Australia)

Author keywords

Commentary; Cost of illness; Health care costs; Intervention studies; Programme evaluation; Psychotic disorders

Indexed keywords

ARTICLE; AWARENESS; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; EMPLOYMENT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; MEDICAL DECISION MAKING; MENTAL HEALTH CARE; PSYCHOSIS; PSYCHOSOCIAL CARE; REHABILITATION; RESOURCE ALLOCATION; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH CARE RATIONING; HEALTH EXPENDITURES; HUMANS; MENTAL HEALTH SERVICES; NEW ZEALAND; PREVALENCE; PROGRAM EVALUATION; PSYCHOTIC DISORDERS; RESOURCE ALLOCATION;

EID: 0346034587     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2003.01117.x     Document Type: Article

References (45)

1. Carr VJ, Neil AL, Halpin SA, Holmes S, Lewin TJ. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Australian and New Zealand Journal of Psychiatry 2003; 37:31-40.
2. Andrews G, Hall W, Goldstein G, Lapsley H, Bartels R, Silove D. The economic costs of schizophrenia: implications for public policy. Archives of General Psychiatry 1985; 42:537-543.
3. Hall W, Andrews G, Goldstein G. The costs of schizophrenia. Australian and New Zealand Journal of Psychiatry 1985; 19:3-5.
4. Andrews G. The cost of schizophrenia revisited. Schizophrenia Bulletin 1991; 17:389-394.
5. Langley-Hawthorne C. Modeling the lifetime costs of treating schizophrenia in Australia. Clinical Therapeutics 1997; 19:1470-1495.
6. Singh B, Hawthorne G, Vos T. The role of economic evaluation in mental health care. Australian and New Zealand Journal of Psychiatry 2001; 35:104-117.
7. Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I. Resperidone versus Haloperidol. II. Cost-effectiveness. Clinical Therapeutics 1998; 20:196-213.
8. Mihalopoulos C, McGorry PD, Carter RC. Is phase-specific, community-oriented treatment of early psychosis an economically viable method of improving outcome? Acta Psychiatrica Scandinavica 1999; 100:47-55.
9. Andrews G. Managing scarcity: a worked example using burden and efficacy. Australasian Psychiatry 1997; 5:225-227.
10. Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, Morgan V, Korten A. People living with psychotic illness: an Australian study 1997-98. National Survey of Mental Health and Wellbeing, Report 4. Canberra: Mental Health Branch Australian Commonwealth Department of Health and Aged Care, 1999.
11. Jablensky A, McGrath J, Herrman H et al. Psychotic disorders in urban areas: an overview of the methods and findings of the study on low prevalence disorders. Australian and New Zealand Journal of Psychiatry 2000; 34:221-236.
12. Carr V, Neil A, Halpin S, Holmes S. Costs of psychosis in urban Australia. A bulletin of the Low Prevalence Disorders Study. Canberra: Mental Health Branch Australian Commonwealth Department of Health and Aged Care, 2002. [Cited 17 October 2002.] Available from URL: http://www.health.gov.au/hsdd/mentalhe/resources/reports/costs.htm
13. Knapp M, Almond S, Percudani M. Costs of schizophrenia: a review. In: Maj M, Sartorius N, eds. Schizophrenia WPA series in evidence and experience in psychiatry, vol. 2. Chichester: Wiley, 1999; 407-454.
14. Goeree R, O'Brien BJ, Goering P et al. The economic burden of schizophrenia in Canada. Canadian Journal of Psychiatry 1999; 44:464-472.
15. Carr VJ, Lewin TJ, Barnard RE et al. Comparisons between schizophrenia patients recruited from Australian general practices and public mental health services. Acta Psychiatrica Scandinavica 2002; 105:346-355.
16. Singh BS, McGorry PD. The Second National Mental Health Plan: an opportunity to take stock and move forward. Medical Journal of Australia 1998; 169:435-437.
17. Andrews G. Meeting the unmet need with disease management. In: Andrews G, Henderson S, eds. Unmet need in psychiatry: problems, resources, responses. Cambridge: Cambridge University Press, 2000; 11-36.
18. Calman KC. The ethics of allocation of scarce health care resources: a view from the centre. Journal of Medical Ethics 1994; 20:71-74.
19. Andrews G. Is schizophrenia worth the cost?. In: Maj M, Sartorius N, eds. Schizophrenia WPA series in evidence and experience in psychiatry, vol. 2. Chichester: Wiley, 1999; 455-457.
20. Nord E, Pinto JL, Richardson J, Menzel P, Ubel P. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Economics 1999; 8:25-39.
21. Ubel PA, Nord E, Gold M, Menzel P, Prades JLP, Richardson J. Improving value measurement in cost-effectiveness analysis. Medical Care 2000; 38:892-901.
22. Murray CJL, Lopez AD, eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard School of Public Health on behalf of the World Health Organization and the World Bank, 1966.
23. Williams A. Calculating the global burden of disease: time for a strategic reappraisal? Health Economics 1999; 8:1-8.
24. Mooney G, Wiseman V. Burden of disease and priority setting. Health Economics 2000; 9:369-372.
25. Murray CJL, Lopez AD. Progress and directions in refining the global burden of disease approach: a response to Williams. Health Economics 2000; 9:69-82.
26. Williams A. Comments on the response by Murray and Lopez. Health Economics 2000; 9:83-86.
27. Evans DB, Hurley SF. The application of economic evaluation techniques in the health sector: the state of the art. Journal of International Development 1995; 7:503-524.
28. Anand S, Hanson K. Disability-adjusted life years: a critical review. Journal of Health Economics 1997; 16:685-702.
29. Goldman HH, Thelander S, Westrin C-G. Organizing mental health services: an evidence-based approach. Journal of Mental Health Policy and Economics 2000; 3:69-75.
30. Andrews G, Sanderson K, Corry J, Lapsley HM. Using epidemiological data to model efficiency in reducing the burden of depression. Journal of Mental Health Policy and Economics 2000; 3:175-186.
31. Rice DP. Cost of illness studies - fact or fiction. Lancet 1994; 344:1519-1520.
32. Mugford M, Cooper NJ. The value of COI studies. Electronic responses to: Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. [Cited 17 May, 2000.] Available from URL: http://www.bmj.com/cgi/eletters/320/7245/1335#EL1
33. Andrews G, Sanderson K, Slade T, Issakidis C. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bulletin of the World Health Organization 2000; 78:446-454.
34. Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders (Cochrane Review). In: The Cochrane Library. Oxford: Update Software 2002, Issue 1.
35. Pharoah FM, Mari JJ, Streiner D. Family intervention of schizophrenia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software 2002, Issue 1.
36. Pekkala E, Merinder L. Psychoeducation for schizophrenia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software 2002, Issue 1.
37. Crowther R, Marshall M, Bond G, Huxley P. Vocational rehabilitation for people with severe mental illness (Cochrane Review). In: The Cochrane Library. Oxford: Update Software 2002, Issue 1.
38. Cormac I, Jones C, Campbell C. Cognitive behaviour therapy for schizophrenia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software 2002, Issue 1.
39. McGlashen TH. Early detection and intervention in schizophrenia research. Schizophrenia Bulletin 1996; 22:327-345.
40. McGorry PD. The nature of schizophrenia: signposts to prevention. Australian and New Zealand Journal of Psychiatry 2000; 34 (Suppl.): 14-21.
41. Nathan PE, Gorman JM. A guide to treatments that work. New York: Oxford University Press, 1998.
42. Mueser KT, Drake RE, Bond GR. Recent advances in psychiatric rehabilitation for patients with severe mental illness. Harvard Review of Psychiatry 1997; 5:123-137.
43. Mueser KT, Bond GR, Drake RE. Community-based treatment of schizophrenia and other severe mental disorders: treatment outcomes? Medscape Psychiatry and Mental Health Journal 2001, 6. [Cited 15 October 2002.] Available from URL: http://www.medscape.com/viewarticle/430529
44. Crowther RE, Marshall M, Bond GR, Huxley P. Helping people with severe mental illness to obtain work. British Medical Journal 2001; 322:204-208.
45. Healey A, Knapp M, Astin J et al. Cost-effectiveness evaluation of compliance therapy for people with psychosis. British Journal of Psychiatry 1998; 172:420-424.